The DOI matches its Crossref record; 628 of the 628 references it cites were found in a registry or an index.
Targeting cytokine and chemokine signaling pathways for cancer therapy
Open accessAbstract
Cytokines are critical in regulating immune responses and cellular behavior, playing dual roles in both normal physiology and the pathology of diseases such as cancer. These molecules, including interleukins, interferons, tumor necrosis factors, chemokines, and growth factors like TGF-β, VEGF, and EGF, can promote or inhibit tumor growth, influence the tumor microenvironment, and impact the efficacy of cancer treatments. Recent advances in targeting these pathways have shown promising therapeutic potential, offering new strategies to modulate the immune system, inhibit tumor progression, and overcome resistance to conventional therapies. In this review, we summarized the current understanding and therapeutic implications of targeting cytokine and chemokine signaling pathways in cancer. By exploring the roles of these molecules in tumor biology and the immune response, we highlighted the development of novel therapeutic agents aimed at modulating these pathways to combat cancer. The review elaborated on the dual nature of cytokines as both promoters and suppressors of tumorigenesis, depending on the context, and discussed the challenges and opportunities this presents for therapeutic intervention. We also examined the latest advancements in targeted therapies, including monoclonal antibodies, bispecific antibodies, receptor inhibitors, fusion proteins, engineered cytokine variants, and their impact on tumor growth, metastasis, and the tumor microenvironment. Additionally, we evaluated the potential of combining these targeted therapies with other treatment modalities to overcome resistance and improve patient outcomes. Besides, we also focused on the ongoing research and clinical trials that are pivotal in advancing our understanding and application of cytokine- and chemokine-targeted therapies for cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 401–600 of 628
Algazi, A. P., Bhatia, S., Agarwala, S. S., Molina, M., Lewis, K. D., Faries, M. B., Fong, L. H., Levine, L. P., Franco, M., Oglesby, A., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.12.008 · Cited by 138
CXCR4 antagonist AMD3100 (plerixafor): From an impurity to a therapeutic agent
Wang, J., Tannous, B. A., Poznansky, M. C., & Chen, H. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105010 · Cited by 138
Rolling-translated EGFR variants sustain EGFR signaling and promote glioblastoma tumorigenicity
Liu, Y., Li, Z., Zhang, M., Zhou, H., Wu, X., Zhong, J., Xiao, F., Huang, N., Yang, X., Zeng, R., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa279 · Cited by 138
Zhou, C., Weng, J., Liu, C., Liu, S., Hu, Z., Xie, X., Gao, D., Zhou, Q., Sun, J., Xu, R.-C., et al. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.02.005 · Cited by 138
Interleukin-10 in cancer immunotherapy: from bench to bedside
Salkeni, M. A., & Naing, A. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.05.003 · Cited by 137
Montagut, C., Argilés, G., Ciardiello, F., Poulsen, T. T., Dienstmann, R., Kragh, M., Kopetz, S., Lindsted, T., Ding, C., Vidal, J., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.5245 · Cited by 135
Ohno, Y., Kitamura, H., Takahashi, N., Ohtake, J., Kaneumi, S., Sumida, K., Homma, S., Kawamura, H., Minagawa, N., Shibasaki, S., et al. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1791-4 · Cited by 134
Regulation of IFN-γ Signaling Is Essential for the Cytotoxic Activity of CD8+ T Cells
Tau, G. Z., Cowan, S., Weisburg, J. H., Braunstein, N. S., & Rothman, P. B. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.10.5574 · Cited by 133
Two Mechanistically and Temporally Distinct NF-κB Activation Pathways in IL-1 Signaling
Yamazaki, K., Gohda, J., Kanayama, A., Miyamoto, Y., Sakurai, H., Yamamoto, M., Akira, S., Hayashi, H., Su, B., & Inoue, J. (2009) · Science Signaling · doi:10.1126/scisignal.2000387 · Cited by 133
Li, H., Lan, T., Liu, H., Liu, C., Dai, J., Xu, L., Cai, Y., Hou, G., Xie, K., Liao, M., et al. (2021) · Hepatology · doi:10.1002/hep.32232 · Cited by 133
IL6 Trans-signaling Promotes KRAS-Driven Lung Carcinogenesis
Brooks, G. D., McLeod, L., Alhayyani, S., Miller, A., Russell, P. A., Ferlin, W. G., Rose‐John, S., Ruwanpura, S. M., & Jenkins, B. J. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2388 · Cited by 132
Hecht, J. R., Lonardi, S., Bendell, J. C., Sim, H., Macarulla, T. M., Lopez, C. D., Cutsem, E. V., Martín, A. J. M., Park, J. O., Greil, R., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02232 · Cited by 132
Zitvogel, L., Tahara, H., Cai, Q., Storkus, W. J., Müller, G., Wolf, S. F., Gately, M. K., Robbins, P. D., & Lotze, M. T. (1994) · Human Gene Therapy · doi:10.1089/hum.1994.5.12-1493 · Cited by 131
Naing, A., Wong, D. J. L., Infante, J. R., Korn, W. M., Aljumaily, R. M., Papadopoulos, K. P., Autio, K. A., Pant, S., Bauer, T. M., Drakaki, A., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30514-5 · Cited by 131
Potential Role of CXCR4 Targeting in the Context of Radiotherapy and Immunotherapy of Cancer
Eckert, F., Schilbach, K., Klumpp, L., Bardoscia, L., Sezgın, E., Schwab, M. G., Zips, D., & Huber, S. M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03018 · Cited by 130
The Complexity of Translating Anti-angiogenesis Therapy from Basic Science to the Clinic
Ye, W. (2016) · Developmental Cell · doi:10.1016/j.devcel.2016.03.015 · Cited by 129
Montfort, A., Filleron, T., Virazels, M., Dufau, C., Milhès, J., Pagès, C., Olivier, P., Ayyoub, M., Mounier, M., Lusque, A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3449 · Cited by 129
Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1B
Musella, M., Guarracino, A., Manduca, N., Galassi, C., Ruggiero, E., Potenza, A., Maccafeo, E., Manic, G., Mattiello, L., Rehim, S. S. A., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01290-3 · Cited by 129
Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors
Oh, D., Lee, S., Han, S., Kim, M., Kim, T.-M., Kim, T., Heo, D. S., Yuasa, M., Yanagihara, Y., & Bang, Y. (2015) · Cancer Research and Treatment · doi:10.4143/crt.2014.249 · Cited by 128
Alberts, D. S., Marth, C., Alvarez, R. D., Johnson, G. A., Bidziński, M., Kardatzke, D. R., Bradford, W. Z., Loutit, J. S., Kirn, D. H., Clouser, M. C., et al. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.01.005 · Cited by 127
Goumas, F. A., Holmer, R., Egberts, J., Gontarewicz, A., Heneweer, C., Geisen, U. M., Hauser, C., Mende, M., Legler, K., Röcken, C., et al. (2015) · International Journal of Cancer · doi:10.1002/ijc.29445 · Cited by 126
Interferon-α Suppresses cAMP to Disarm Human Regulatory T Cells
Bacher, N., Raker, V., Hofmann, C., Graulich, E., Schwenk, M., Baumgrass, R., Bopp, T., Zechner, U., Merten, L., Becker, C., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3788 · Cited by 124
Cancer cell-derived IL-1α induces CCL22 and the recruitment of regulatory T cells
Wiedemann, G. M., Knott, M. M. L., Vetter, V. K., Rapp, M., Haubner, S., Fesseler, J., Kühnemuth, B., Layritz, P., Thaler, R., Krüger, S., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1175794 · Cited by 123
Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy
Skrombolas, D., & Frelinger, J. G. (2014) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.875856 · Cited by 122
Niu, M., Yi, M., Wu, Y., Lyu, L., He, Q., Yang, R., Zeng, L., Shi, J. Y., Zhang, J., Zhou, P., et al. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01487-5 · Cited by 122
Self-citationRegulation of lymphoid homeostasis by interleukin-15
Lodolce, J. P., Burkett, P. R., Koka, R., Boone, D. L., & Ma, A. I. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(02)00029-1 · Cited by 121
Zhao, G., Zhu, G., Huang, Y., Zheng, W., Jin, H., Yang, S., Zhuang, J., & Ye, J. (2016) · Oncology Reports · doi:10.3892/or.2016.4544 · Cited by 121
IRF9 and unphosphorylated STAT2 cooperate with NF-κB to drive IL6 expression
Jing, N., Wang, Y., Yang, J. B., & Stark, G. R. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1714102115 · Cited by 121
Oncogenic BRAFV600E Governs Regulatory T-cell Recruitment during Melanoma Tumorigenesis
Shabaneh, T. B., Molodtsov, A. K., Steinberg, S. M., Zhang, P., Torres, G. M., Mohamed, G. A., Boni, A., Curiel, T. J., Angeles, C. V., & Turk, M. J. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0365 · Cited by 120
Lau, L., Porciuncula, A., Yu, A., Iwakura, Y., & David, G. (2019) · Molecular and Cellular Biology · doi:10.1128/mcb.00586-18 · Cited by 119
C-MET inhibitors for advanced non-small cell lung cancer
Pasquini, G., & Giaccone, G. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1462336 · Cited by 119
Lee, S. J., Yang, H., Kim, W. R., Lee, Y. S., Lee, W. S., Kong, S. J., Lee, H. J., Kim, J. H., Cheon, J., Kang, B., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002195 · Cited by 118
Nguyen, L. S., Bretagne, M., Arrondeau, J., Zahr, N., Éderhy, S., Abbar, B., Pinna, B., Allenbach, Y., Mira, J. P., Moslehi, J. J., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004699 · Cited by 118
Haag, G. M., Springfeld, C., Grün, B., Apostolidis, L., Zschäbitz, S., Dietrich, M., Berger, A.-K., Weber, T. F., Zoernig, I., Schaaf, M., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.03.017 · Cited by 118
STAT3 mediates TGF-β1-induced TWIST1 expression and prostate cancer invasion
Cho, K. H., Jeong, K. J., Shin, S. C., Kang, J., Park, C. G., & Lee, H. Y. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.04.024 · Cited by 117
TGF beta −1, −2 and −3 in the modulation of fibrosis in the cornea and other organs
Wilson, S. E. (2021) · Experimental Eye Research · doi:10.1016/j.exer.2021.108594 · Cited by 116
Diagnosis and Treatment of ERBB2-Positive Metastatic Colorectal Cancer: A Review
Strickler, J. H., Yoshino, T., Graham, R. P., Siena, S., & Bekaii‐Saab, T. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2021.8196 · Cited by 116
The potential to target CCL5/CCR5 in breast cancer
Velasco-Velázquez, M. A., Xolalpa, W., & Pestell, R. G. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.949238 · Cited by 115
Bendell, J. C., Hong, D. S., Burris, H. A., Naing, A., Jones, S. F., Falchook, G., Bricmont, P., Elekes, A., Rock, E. P., & Kurzrock, R. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2480-2 · Cited by 115
A Phase I Trial of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Advanced Cancer
Galsky, M. D., Vogelzang, N. J., Conkling, P., Raddad, E., Polzer, J. P., Roberson, S., Stille, J. R., Saleh, M. N., & Thornton, D. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2686 · Cited by 115
Genetic Engineering of Hematopoiesis for Targeted IFN-α Delivery Inhibits Breast Cancer Progression
Escobar, G., Moi, D., Ranghetti, A., Baydin, P. O., Squadrito, M. L., Kajaste‐Rudnitski, A., Bondanza, A., Gentner, B., Palma, M. D., Mazzieri, R., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3006353 · Cited by 114
Thomas, R. P., Nagpal, S., Iv, M., Soltys, S. G., Bertrand, S., Pelpola, J. S., Ball, R. L., Yang, J., H, V. S. M. P., Chernikova, S. B., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1421 · Cited by 114
Blocking Tumor Necrosis Factor α Enhances CD8 T-cell–Dependent Immunity in Experimental Melanoma
Bertrand, F., Rochotte, J., Colacios, C., Montfort, A., Tilkin-Mariamé, A.-F., Touriol, C., Rochaix, P., Lajoie-Mazenc, I., Andrieu-Abadie, N., Levade, T., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2524 · Cited by 113 · cited 1×
“326 Moreover, TNF undermines the antitumor activity of NK cells by upregulating TIM-3 and downregulating NKp46.”
BackgroundChertova, E. N., Bergamaschi, C., Chertov, O., Sowder, R. C., Bear, J., Roser, J. D., Beach, R. K., Lifson, J. D., Felber, B. K., & Pavlakis, G. N. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.461756 · Cited by 113
Liu, Z., Ravindranathan, R., Li, J., Kalinski, P., Guo, Z. S., & Bartlett, D. L. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1091554 · Cited by 113
Thorn, M., Guha, P., Cunetta, M., Espat, N. J., Miller, G., Junghans, R. P., & Katz, S. C. (2016) · Cancer Gene Therapy · doi:10.1038/cgt.2016.19 · Cited by 113
A Third Shot at EGFR: New Opportunities in Cancer Therapy
Guardiola, S., Varese, M., Sánchez‐Navarro, M., & Giralt, E. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.10.004 · Cited by 113
Zollo, M., Dato, V. D., Spano, D., Martino, D. D., Liguori, L., Marino, N., Vastolo, V., Navas, L., Garrone, B., Mangano, G., et al. (2012) · Clinical & Experimental Metastasis · doi:10.1007/s10585-012-9473-5 · Cited by 111
Cao, X., Liang, Y., Hu, Z., Li, H., Yang, J., Hsu, E. J., Zhu, J., Zhou, J., & Fu, Y. (2021) · Nature Communications · doi:10.1038/s41467-021-26112-2 · Cited by 111
Papewalis, C., Jacobs, B., Wuttke, M., Ullrich, E., Baehring, T., Fenk, R. R., Willenberg, H. S., Schinner, S., Cohnen, M., Seißler, J., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.3.1462 · Cited by 110
Zheng, Y., Li, Y., Lian, J., Yang, H., Li, F., Zhao, S., Qi, Y., Zhang, Y., & Huang, L. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1917-0 · Cited by 110
Can EGFR be a therapeutic target in breast cancer?
Li, X., Zhao, L., Chen, C., Nie, J., & Jiao, B. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188789 · Cited by 110
Leukocyte-endothelial adhesion and angiogenesis in tumors
Jain, R. K., Koenig, G. C., Dellian, M., Fukumura, D., Munn, L. L., & Melder, R. J. (1996) · Cancer and Metastasis Reviews · doi:10.1007/bf00437472 · Cited by 109
Pañeda, A., Vanrell, L., Mauleon, I., Crettaz, J. S., Berraondo, P., Timmermans, E. J., Beattie, S. G., Twisk, J., van Deventer, S., Prieto, J., et al. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.031 · Cited by 109
Baganizi, D. R., Nyairo, E., Duncan, S. A., Singh, S. R., & Dennis, V. A. (2017) · Nanomaterials · doi:10.3390/nano7070165 · Cited by 109
Anwer, K., Barnes, M. N., Fewell, J. G., Lewis, D. H., & Alvarez, R. D. (2009) · Gene Therapy · doi:10.1038/gt.2009.159 · Cited by 108
A CCR4 antagonist reverses the tumor-promoting microenvironment of renal cancer
Berlato, C., Khan, M. N., Schioppa, T., Thompson, R. D., Maniati, E., Montfort, A., Jangani, M., Canosa, M., Kulbe, H., Hagemann, U. B., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci82976 · Cited by 108
Yu, S., Liu, Q., Han, X., Qin, S., Zhao, W., Li, A., & Wu, K. (2017) · Experimental Hematology and Oncology · doi:10.1186/s40164-017-0091-4 · Cited by 108
Self-citationNovel strategies exploiting interleukin-12 in cancer immunotherapy
Cirella, A., Luri‐Rey, C., Trani, C. A. D., Teijeira, Á., Olivera, I., Bolaños, E., Álvarez, E. C., Palencia, B., Brocco, D., Fernández-Sendin, M., et al. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108189 · Cited by 108
Ding, L., Wang, Q., Martincuks, A., Kearns, M. J., Jiang, T., Lin, Z., Cheng, X., Qian, C., Xie, S., Kim, H., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005627 · Cited by 106
Suzuki, S., Yonesaka, K., Teramura, T., Takehara, T., Kato, R., Sakai, H., Haratani, K., Tanizaki, J., Kawakami, H., Hayashi, H., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0856 · Cited by 105
Ghobrial, I. M., Liu, C., Redd, R. A., Perez, R. P., Baz, R., Zavidij, O., Sklavenitis‐Pistofidis, R., Richardson, P. G. G., Anderson, K. C., Laubach, J. P., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0647 · Cited by 105
Han, R. F., Gu, S., Zhang, Y., Luo, A., Jing, X., Zhao, L., Zhao, X., & Zhang, L. (2018) · Scientific Reports · doi:10.1038/s41598-018-27810-6 · Cited by 104
Nagato, T., Lee, Y.-R., Harabuchi, Y., & Celis, E. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2781 · Cited by 103
Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study
Lassman, A. B., Sepúlveda-Sánchez, J. M., Cloughesy, T. F., Gil-Gil, M. J., Puduvalli, V. K., Raizer, J. J., Vos, F. D., Wen, P. Y., Butowski, N. A., Clément, P. M., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2664 · Cited by 102
Crizotinib in the treatment of non-small-cell lung cancer
Forde, P. M., & Rudin, C. M. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.688029 · Cited by 101
Isambert, N., Hervieu, A., Rébé, C., Hennequin, A., Borg, C., Zanetta, S., Chevriaux, A., Richard, C., Dérangère, V., Limagne, E., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1474319 · Cited by 101
TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy
Yi, M., Li, T., Niu, M., Wu, Y., Zhao, Z., & Wu, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1061394 · Cited by 101
Self-citationRen, Z., Zhang, A., Sun, Z., Liang, Y., Ye, J., Qiao, J., Li, B., & Fu, Y. (2022) · Journal of Clinical Investigation · doi:10.1172/jci153604 · Cited by 100
Urdinguio, R. G., Fernández, A. F., Moncada-Pazos, Á., Huidobro, C., Rodríguez, R. M. A., Ferrero, C., Martínez‐Camblor, P., Obaya, Á. J., Bernal, T., Parra‐Blanco, A., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0806 · Cited by 99
Du, Z., Ng, Y. Y., Zha, S., & Wang, S. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.10.014 · Cited by 99
Holmstroem, R. B., Nielsen, O. H., Jacobsen, S., Riis, L. B., Theile, S., Bjerrum, J. T., Vilmann, P., Johansen, J. S., Boisen, M. K., Eefsen, R. L., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005111 · Cited by 98
PLEK2 promotes gallbladder cancer invasion and metastasis through EGFR/CCL2 pathway
Shen, H., He, M. Y., Lin, R., Zhan, M., Xu, S., Huang, X., Chu, X., Chen, W., Yao, Y., Mohan, M., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1250-8 · Cited by 97
Greaney, S. K., Algazi, A. P., Tsai, K. K., Takamura, K. T., Chen, L., Twitty, C., Zhang, L., Paciorek, A. T., Pierce, R. H., Le, M. H., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0359 · Cited by 97
Tumor-conditional IL-15 pro-cytokine reactivates anti-tumor immunity with limited toxicity
Guo, J., Liang, Y., Xue, D., Shen, J., Cai, Y., Zhu, J., Fu, Y., & Peng, H. (2021) · Cell Research · doi:10.1038/s41422-021-00543-4 · Cited by 96
CCR4 Blockade Depletes Regulatory T Cells and Prolongs Survival in a Canine Model of Bladder Cancer
Maeda, S., Murakami, K., Inoue, A., Yonezawa, T., & Matsuki, N. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0751 · Cited by 95
Wang, H., Chen, C.-W., Yang, C.-L., Tsai, I.-M., Hou, Y., Chen, C.-J., & Shan, Y. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0295 · Cited by 93
Interleukin 15 in Cell-Based Cancer Immunotherapy
Zhou, Y., Husman, T., Cen, X., Tsao, T., Brown, J., Bajpai, A., Li, M., Zhou, K., & Yang, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137311 · Cited by 92
Liu, D., Zhou, J., Wang, Y., Li, M., Jiang, H., Liu, Y., Yin, X., Ge, M., Xiang, X., Ying, J., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02605-9 · Cited by 91
IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma
Reijers, I. L. M., Rao, D., Versluis, J. M., Menzies, A. M., Dimitriadis, P., Wouters, M. W. J. M., Spillane, A. J., Klop, W. M. C., Broeks, A., Bosch, L. J. W., et al. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20221952 · Cited by 91
HCMV Activates the IL-6-JAK-STAT3 Axis in HepG2 Cells and Primary Human Hepatocytes
Lepiller, Q., Abbas, W., Kumar, A., Tripathy, M. K., & Herbein, G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059591 · Cited by 90
Engineering cytokines for cancer immunotherapy: a systematic review
Fu, Y., Tang, R., & Zhao, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1218082 · Cited by 90
Engineered IL-10 variants elicit potent immunomodulatory effects at low ligand doses
Gorby, C., Bellón, J. S., Wilmes, S., Warda, W., Pöhler, E., Fyfe, P. K., Cozzani, A., Ferrand, C., Walter, M. R., Mitra, S., et al. (2020) · Science Signaling · doi:10.1126/scisignal.abc0653 · Cited by 88
Ghouse, S. M., Nguyen, H.-M., Bommareddy, P. K., Guz-Montgomery, K., & Saha, D. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00384 · Cited by 87
Piper, M., Hoen, M., Darragh, L. B., Knitz, M. W., Nguyen, D., Gadwa, J., Durini, G., Hutter-Karakoc, I., Grier, A., Neupert, B., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.04.001 · Cited by 87
Cetuximab for treating non-small cell lung cancer
Mazzarella, L., Guida, A., & Curigliano, G. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1452906 · Cited by 86
Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma
Davar, D., Wang, H., Chauvin, J.-M., Pagliano, O., Fourcade, J. J., Ka, M., Menna, C., Rose, A., Sander, C., Borhani, A. A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.00632 · Cited by 86
Targeting Glutamine Metabolism to Enhance Immunoprevention of EGFR‐Driven Lung Cancer
Huang, M., Xiong, D., Pan, J., Zhang, Q., Sei, S., Shoemaker, R. H., Lubet, R. A., Montuenga, L. M., Wang, Y., Slusher, B. S., et al. (2022) · Advanced Science · doi:10.1002/advs.202105885 · Cited by 85
Vascular normalization in immunotherapy: A promising mechanisms combined with radiotherapy
Liu, Z., Zhao, Q., Zheng, Z., Liu, S., Meng, L., Dong, L., & Jiang, X. M. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111607 · Cited by 83
Model of interaction of the IL‐1 receptor accessory protein IL‐1RAcP with the IL‐1β/IL‐1RI complex
Casadio, R., Frigimelica, E., Bossù, P., Neumann, D., Martin, M. U., Tagliabue, A., & Boraschi, D. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)02515-7 · Cited by 82
Four, S. D., Maenhout, S. K., Niclou, S. P., Thielemans, K., Neyns, B., & Aerts, J. L. (2016) · PubMed · Cited by 80
Brikos, C., Wait, R., Begum, S., O'Neill, L. A. J., & Saklatvala, J. (2007) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m600455-mcp200 · Cited by 79
Lu, Q., Chen, R., Du, S., Chen, C., Pan, Y., Luan, X., Yang, J., Zeng, F., He, B., Han, X., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121871 · Cited by 78
IL-2-driven CD8+ T cell phenotypes: implications for immunotherapy
Niederlová, V., Tsyklauri, O., Kovář, M., & Štěpánek, O. (2023) · Trends in Immunology · doi:10.1016/j.it.2023.09.003 · Cited by 78
Watson, D. C., Moysi, E., Valentin, A., et al. (2018) · PLoS Pathogens · doi:10.1371/journal.ppat.1006902 · Cited by 77
Treatment of Aggressive T Cell Lymphoblastic Lymphoma/leukemia Using Anti-CD5 CAR T Cells
Feng, J., Xu, H.-C., Cinquina, A., Wu, Z., Chen, Q., Zhang, P., Wang, X., Shan, H., Xu, L., Zhang, Q., et al. (2021) · Stem Cell Reviews and Reports · doi:10.1007/s12015-020-10092-9 · Cited by 77
Self-citationLang, K., Niggemann, B., Zänker, K. S., & Entschladen, F. (2002) · International Journal of Cancer · doi:10.1002/ijc.10424 · Cited by 76
Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study
Lassman, A. B., Sepúlveda-Sánchez, J. M., Cloughesy, T. F., Gil‐Gil, M., Puduvalli, V. K., Raizer, J. J., Vos, F. D., Wen, P. Y., Butowski, N. A., Clément, P. M., et al. (2022) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-230044 · Cited by 76
Molecular Pathways and Mechanisms of HER2 in Cancer Therapy
Raghav, K. P. S., & Moasser, M. M. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0283 · Cited by 76
Cytokines in oncolytic virotherapy
Pol, J. G., Workenhe, S. T., Konda, P., Gujar, S. A., & Kroemer, G. (2020) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2020.10.007 · Cited by 75
Chard, L. S., Maniati, E., Wang, P., Zhang, Z., Gao, D., Wang, J., Cao, F., Ahmed, J., Khouri, M. E., Hughes, J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0464 · Cited by 74
Cabozantinib for the treatment of kidney cancer
Abdelaziz, A., & Vaishampayan, U. N. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1344553 · Cited by 74
Battaglin, F., Dadduzio, V., Bergamo, F., Manai, C., Schirripa, M., Lonardi, S., Zagonel, V., & Loupakis, F. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1356815 · Cited by 74
Aomatsu, K., Arao, T., Sugioka, K., MATSUMOTO, K. Y., Tamura, D., Kudo, K., Kaneda, H., Tanaka, K., Fujita, Y., Shimomura, Y., et al. (2010) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.10-5635 · Cited by 73
Goto, S., Sakoda, Y., Adachi, K., Sekido, Y., Yano, S., Eto, M., & Tamada, K. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02853-3 · Cited by 72
Cytokine Based Immunotherapy for Cancer and Lymphoma: Biology, Challenges and Future Perspectives
Atallah‐Yunes, S. A., & Robertson, M. J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.872010 · Cited by 72
Hudes, G., Tagawa, S., Whang, Y., Qi, M., Qin, X., Puchalski, T., Reddy, M., Cornfeld, M., & Eisenberger, M. (2013) · Investigational new drugs · doi:10.1007/s10637-012-9857-z · Cited by 71
Wu, X., Li, J., Connolly, E. M., Liao, X., Ouyang, J., Giobbie‐Hurder, A., Lawrence, D. P., McDermott, D. F., Murphy, G. F., Zhou, J. M., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0385 · Cited by 71
Biological Significance and Targeting of the FGFR Axis in Cancer
Chioni, A., & Grose, R. P. (2021) · Cancers · doi:10.3390/cancers13225681 · Cited by 70
Interferon-ε is a tumour suppressor and restricts ovarian cancer
Marks, Z. R. C., Campbell, N. K., Mangan, N. E., Vandenberg, C. J., Gearing, L. J., Matthews, A. Y., Gould, J. A., Tate, M. D., Wray‐McCann, G., Ying, L., et al. (2023) · Nature · doi:10.1038/s41586-023-06421-w · Cited by 69
Ray, K., Újvári, B., Ramana, V., & Donald, J. A. (2018) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2018.04.002 · Cited by 68
Zamarin, D., Hamid, O., Nayak-Kapoor, A., Sahebjam, S., Sznol, M., Collaku, A., Fox, F. E., Marshall, M. A., & Hong, D. S. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0328 · Cited by 68
Feng, H., Liu, K., Shen, X., Liang, J., Wang, C., Qiu, W., Cheng, X., & Zhao, R. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03111-7 · Cited by 68
Feng, J., Tang, D., Wang, J., Zhou, Q., Peng, J., Lou, H., Sun, Y., Cai, Y., Chen, H., Yang, J., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0346 · Cited by 68
Enhancement of Immunity by a DNA Melanoma Vaccine against TRP2 with CCL21 as an Adjuvant
Yamano, T., Kaneda, Y., Huang, S., Hiramatsu, S. H., & Hoon, D. S. �. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.05.018 · Cited by 67
Schiller, J. H., Pugh, M., Kirkwood, J. M., Karp, D. D., Larson, M., & Borden, E. C. (1996) · PubMed · Cited by 66
Aebersold, D. M., Landt, O., Berthou, S., Gruber, G., Beer, K. T., Greiner, R. H., & Zimmer, Y. (2003) · Oncogene · doi:10.1038/sj.onc.1206968 · Cited by 66
Mota, J. M., Leite, C. A., de Souza, L. E. B., Melo, P. H., Nascimento, D. C., Wagatsuma, V. M. D. D., Temporal, J., Figueiredo, F., Noushmehr, H., Alves-Filho, J. C., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0170 · Cited by 66
Targeting the IL-1β/EHD1/TUBB3 axis overcomes resistance to EGFR-TKI in NSCLC
Huang, J., Lan, X., Wang, T., Lu, H., Cao, M., Yan, S., Cui, Y., Jia, D., Cai, L., & Xing, Y. (2019) · Oncogene · doi:10.1038/s41388-019-1099-5 · Cited by 66
Yanaihara, N., Hirata, Y., Yamaguchi, N., Noguchi, Y., Saito, M., Nagata, C., Takakura, S., Yamada, K., & Okamoto, A. (2015) · Molecular Carcinogenesis · doi:10.1002/mc.22325 · Cited by 65
Yang, Z., Li, H., Wang, W., Zhang, J., Jia, S., Wang, J., Wei, J., Lei, D., Hu, K., & Yang, X. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00231 · Cited by 65
Baysal, H., Pauw, I. D., Zaryouh, H., Peeters, M., Vermorken, J. B., Lardon, F., Waele, J. D., & Wouters, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.737311 · Cited by 65
Wiesenfeld, M., O'Connell, M. J., Wieand, H. S., Gonchoroff, N. J., Donohue, J. H., Fitzgibbons, R. J., Krook, J. E., Mailliard, J. A., Gerstner, J. B., & Pazdur, R. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.9.2324 · Cited by 64
Barton, K. N., Siddiqui, F., Pompa, R., Freytag, S. O., Khan, G. N., Dobrosotskaya, I. Y., Ajlouni, M., Zhang, Y., Cheng, J., Movsas, B., et al. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.11.006 · Cited by 64
Wang, K., Chen, Q., Liu, N., Zhang, J., & Pan, X. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.07.024 · Cited by 63
Challenges for the application of EGFR-targeting peptide GE11 in tumor diagnosis and treatment
Tang, H., Yonghong, P., Yu-feng, Z., & Haitao, T. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.07.018 · Cited by 63
Bispecific antibody targeting TGF-β and PD-L1 for synergistic cancer immunotherapy
Li, T., Wang, X., Niu, M., Wang, M., Zhou, J., Wu, K., & Yi, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1196970 · Cited by 63
Self-citationDesign of a superior cytokine antagonist for topical ophthalmic use
Hou, J., Townson, S. A., Kovalchin, J. T., Masci, A., Kiner, O., Shu, Y., King, B. M., Schirmer, E. B., Golden, K., Thomas, C., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1217996110 · Cited by 62
Role of HGF/MET axis in resistance of lung cancer to contemporary management.
Raghav, K. P. S., Gonzalez-Angulo, A. M., & Blumenschein, G. R. (2012) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2012.09.04 · Cited by 60
Mu, X., Wang, R.-J., Yao, Z., Zheng, Z., Jiang, J., Tan, M., Sun, F., Fan, J., Wang, X., Zheng, J., et al. (2019) · Molecular Immunology · doi:10.1016/j.molimm.2019.02.014 · Cited by 60
Self-citationMorris, T. A., Khoo, C., & Solomon, B. (2019) · Drugs · doi:10.1007/s40265-019-01164-3 · Cited by 59
NKTR-255, a novel polymer-conjugated rhIL-15 with potent antitumor efficacy
Miyazaki, T., Maiti, M., Hennessy, M., Chang, T., Kuo, P., Addepalli, M. K., Obalapur, P., Sheibani, S., Wilczek, J., Pena, R. L., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002024 · Cited by 59
Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy
García-Martínez, E., Smith, M. M., Buqué, A., Aranda, F., de la Peña, F. A., Rubio, A. I., Cánovas, M. S., Conesa, M. A. V., Fucikova, J. P., Špíšek, R., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1433982 · Cited by 58
Yang, Y., Wang, Y., Ahn, J., Kim, B., & Choi, J. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113474 · Cited by 57
Zhou, K., Xie, L. H., Peng, X., Guo, Q., Wu, Q., Wang, W. H., Zhang, G. L., Wu, J., Zhang, G. J., & Du, C. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.01.009 · Cited by 56
Lythgoe, M. P., & Prasad, V. K. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01893-5 · Cited by 56
Kong, Y., Zhao, X., Xu, M., Pan, J., Ma, Y., Zou, L., Peng, Q., Zhang, J., Su, C., Xu, Z. Z., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.952066 · Cited by 56
Engineering of Macrophages to Produce IFN-γ in Response to Hypoxia
Carta, L., Pastorino, S., Melillo, G., Bosco, M. C., Massazza, S., & Varesio, L. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.9.5374 · Cited by 55
Salem, M. L., Gillanders, W. E., Kadima, A. N., et al. (2006) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2006.26.593 · Cited by 55
The application and research progress of anti-angiogenesis therapy in tumor immunotherapy
Tu, J., Liang, H., Li, C., Huang, Y., Wang, Z., Chen, X., & Yuan, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1198972 · Cited by 55
Tanaka, H., Matsumura, I., Nakajima, K., Daino, H., Sonoyama, J., Yoshida, H., Oritani, K., Machii, T., Yamamoto, M., Hirano, T., et al. (2000) · Blood · doi:10.1182/blood.v95.4.1264.004k09_1264_1273 · Cited by 54
Tian, H., Shi, G., Wang, Q., Li, Y., Yang, Q., Li, C., Yang, G., Wu, M., Xie, Q., Zhang, S., et al. (2016) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2016.25 · Cited by 54
Ren, Z., Zhang, A., Sun, Z., Liang, Y., Ye, J., Qiao, J., Li, B., & Fu, Y. (2022) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 54
CXCR4 Inhibition Counteracts Immunosuppressive Properties of Metastatic NSCLC Stem Cells
Fortunato, O., Belisario, D. C., Compagno, M., Giovinazzo, F., Bracci, C., Pastorino, U., Horenstein, A. L., Malavasi, F., Ferracini, R., Scala, S., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02168 · Cited by 53
Zhang, Y., Zhuang, Q., Wang, F., Zhang, C., Xu, C., Tong, S., An, Z., Hu, Y., Gu, A., Hu, Y., et al. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03626-x · Cited by 53
Garrido, P., Pujol, J.-L., Kim, E. S., Lee, J. M., Tsuboi, M., Gómez‐Rueda, A., Benito, A., Moreno‐Mata, N., Gorospe, L., Dong, T., et al. (2021) · Future Oncology · doi:10.2217/fon-2020-1098 · Cited by 52
Chu, Y., Nayyar, G., Jiang, S., Rosenblum, J., Soon‐Shiong, P., Safrit, J. T., Lee, D. A., & Cairo, M. S. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002267 · Cited by 52
Type I IFN gene delivery suppresses regulatory T cells within tumors
Hashimoto, H., Ueda, R., Narumi, K., Heike, Y., Yoshida, T., & Aoki, K. (2014) · Cancer Gene Therapy · doi:10.1038/cgt.2014.60 · Cited by 51
TNFR2 expression by CD4 effector T cells is required to induce full-fledged experimental colitis
Chen, X., Nie, Y., Xiao, H., Bian, Z., Scarzello, A. J., Song, N., Trivett, A. L., Yang, D., & Oppenheim, J. J. (2016) · Scientific Reports · doi:10.1038/srep32834 · Cited by 51
Nelson, A., Gebremeskel, S., Lichty, B. D., & Johnston, B. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003923 · Cited by 51
Liu, Y., Wang, B., Qin, J., Zhou, H., Majumdar, A. P. N., & Peng, F. (2018) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2017.1417997 · Cited by 50
Guillot, B., Portalès, P., Du-Thanh, A., Merlet, S., Dereure, O., Clot, J., & Corbeau, P. (2005) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2005.06512.x · Cited by 48
Targeting CCR4 as an emerging strategy for cancer therapy and vaccines
Bayry, J., Tartour, É., & Tough, D. F. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.02.003 · Cited by 48
Necitumumab: First Global Approval
Garnock-Jones, K. P. (2016) · Drugs · doi:10.1007/s40265-015-0537-0 · Cited by 48
Desbois, M., Béal, C., Charrier, M., Besse, B., Meurice, G., Cagnard, N., Jacques, Y., Béchard, D., Cassard, L., & Chaput, N. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000632 · Cited by 48
CXC chemokine receptor 4 (CXCR4) blockade in cancer treatment
Bao, S., Darvishi, M., Amin, A. H., Al-Haideri, M. T., Patra, I., Kashikova, K., Ahmad, I., Alsaikhan, F., Al‐qaim, Z. H., Al-Gazally, M. E., et al. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04444-w · Cited by 48
Wu, F. T. H., Xu, P., Chow, A., Man, S., Krüger, J., Khan, K. A., Paez-Ribes, M., Pham, E., & Kerbel, R. S. (2019) · British Journal of Cancer · doi:10.1038/s41416-018-0297-1 · Cited by 47
Impact of tumor-derived CCL2 on T cell effector function
Vitiello, P. F., Shainheit, M. G., Allison, E. M., Adler, E. P., & Kurt, R. A. (2004) · Immunology Letters · doi:10.1016/j.imlet.2003.12.009 · Cited by 46
Song, Z., Gao, Z., Chu, J., Han, X.-Z., & Qu, X. (2015) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2015.01.020 · Cited by 45
Roselli (2009) · International Journal of Oncology · doi:10.3892/ijo_00000259 · Cited by 45
Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma
Harding, J. J., Do, R. K., Yaqubie, A., Cleverly, A., Zhao, Y., Gueorguieva, I., Lahn, M. M. F., Benhadji, K. A., Kelley, R. K., & Abou‐Alfa, G. K. (2021) · Cancer Medicine · doi:10.1002/cam4.3880 · Cited by 45
Fang, L., Zhao, Z., Wang, J., Xiao, P., Sun, X., Ding, Y., Zhang, P., Wang, D., & Li, Y. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.06.006 · Cited by 45
TNFR2/BIRC3-TRAF1 signaling pathway as a novel NK cell immune checkpoint in cancer
Ivagnès, A., Messaoudene, M., Stoll, G., Routy, B., Fluckiger, A., Yamazaki, T., Iribarren, K., Duong, C. P. M., Fend, L., Caignard, A., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1386826 · Cited by 44
Eckert, E. C., Nace, R. A., Tonne, J. M., Evgin, L., Vile, R. G., & Russell, S. J. (2019) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2019.12.003 · Cited by 44
A very long-acting IL-15: implications for the immunotherapy of cancer
Hangasky, J. A., Chen, W., Dubois, S. P., Daenthanasanmak, A., Müller, J. R., Reid, R. R., Waldmann, T. A., & Santi, D. V. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004104 · Cited by 43
Tran, T. T. T., Caulfield, J. I., Zhang, L., Schoenfeld, D. A., Djureinovic, D., Chiang, V., Oria, V. O., Weiss, S. A., Olino, K. L., Jilaveanu, L. B., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.157347 · Cited by 43
Rosen, D. B., Kvarnhammar, A. M., Laufer, B., Knappe, T. A., Karlsson, J. J., Hong, E., Lee, Y., Thakar, D., Zuniga, L. A., Bang, K., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004991 · Cited by 42
Growth factor and signaling pathways and their relevance to prostate cancer therapeutics
Wozney, J. L., & Antonarakis, E. S. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9475-z · Cited by 41
Ilander, M. M., Kreutzman, A. S., Rohoň, P., Melo, T. P. E., Faber, E., Porkka, K., Vakkila, J., & Mustjoki, S. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087794 · Cited by 41
Lin, D., Lei, L., Liu, Y., Zhang, Y., Hu, B., Bao, G., Song, Y., Jin, Z., Liu, C., Mei, Y., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2658 · Cited by 41
Self-citationZhang, R., Roque, D. M., Reader, J. C., & Lin, J. (2022) · International Journal of Oncology · doi:10.3892/ijo.2022.5340 · Cited by 41
Watanabe, M., Fenton, R. G., Wigginton, J. M., et al. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.4.1943 · Cited by 40
Ongaro, T., Matasci, M., Cazzamalli, S., Gouyou, B., Luca, R. D., Neri, D., & Villa, A. (2018) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2018.12.004 · Cited by 40
EGFR and anti-EGFR nanobodies: review and update
Sharifi, J., Khirehgesh, M. R., Safari, F., & Akbari, B. (2020) · Journal of drug targeting · doi:10.1080/1061186x.2020.1853756 · Cited by 40
Wu, Z., & Xu, Y. (2010) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjq012 · Cited by 39
Wang, X., Lü, X., Zhao, H., Zhang, F., & Jiang, X. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1426-6 · Cited by 38
A Novel Role for the Interleukin-1 Receptor Axis in Resistance to Anti-EGFR Therapy
Gelfo, V., Mazzeschi, M., Grilli, G., Lindzen, M., Santi, S., D’Uva, G., Győrffy, B., Ardizzoni, A., Yarden, Y., & Lauriola, M. (2018) · Cancers · doi:10.3390/cancers10100355 · Cited by 38
Mendoza-Rodríguez, M., Ayala-Sumuano, J. T., García-Morales, L., Zamudio‐Meza, H., Pérez-Yépez, E. A., & Meza, I. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20020270 · Cited by 38
Zibelman, M. R., Macfarlane, A. W., Costello, K., McGowan, T., O’Neill, J., Kokate, R. A., Borghaei, H., Denlinger, C. S., Dotan, E., Geynisman, D. M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40028-z · Cited by 38
Vaishampayan, U. N., Tomczak, P., Muzaffar, J., Winer, I. S., Rosen, S. D., Hoimes, C. J., Chauhan, A., Spreafico, A., Lewis, K. D., Bruno, D. S., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.16_suppl.2500 · Cited by 37
Yu, P., Wang, Y., Yuan, D., Sun, Y., Qin, S., & Li, T. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1276694 · Cited by 37
Self-citationBlockade of IL-6 inhibits tumor immune evasion and improves anti–PD-1 immunotherapy
Li, W., Wu, Z., Meng, W., Zhang, C., Cheng, M., Chen, Y., Zou, Y., Li, K., Lin, S., Xiong, W., et al. (2022) · Cytokine · doi:10.1016/j.cyto.2022.155976 · Cited by 36
Rethinking Oncologic Treatment Strategies with Interleukin-2
Ko, B., Takebe, N., Andrews, O., Makena, M. R., & Chen, A. P. (2023) · Cells · doi:10.3390/cells12091316 · Cited by 36
Kusakabe, M., Cheong, P. L., Nikfar, R., McLennan, I. S., & Koishi, K. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21407 · Cited by 35
FGFR-targeted therapeutics for the treatment of breast cancer
Luca, A. D., Frezzetti, D., Gallo, M., & Normanno, N. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1287173 · Cited by 35
Gray, J. E., Chiappori, A., Williams, C. C., Tanvetyanon, T., Haura, E. B., Creelan, B., Kim, J., Boyle, T. A., Pinder-Schenck, M. C., Khalil, F. K., et al. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2236-7 · Cited by 35
GM-CSF Promotes Antitumor Immunity by Inducing Th9 Cell Responses
Kim, I., Koh, C., Jeon, I., Shin, K., Kang, T.-S., Bae, E., Seo, H., Ko, H., Kim, B., Chung, Y., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0518 · Cited by 35
IFN‐α and Novel Strategies of Combination Therapy for Cancer
Bracci, L., Proietti, E., & Belardelli, F. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1415.030 · Cited by 34
Skrombolas, D., Sullivan, M. A., & Frelinger, J. G. (2019) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2018.0129 · Cited by 34
Pertuzumab and breast cancer: another piece in the anti-HER2 puzzle
Gerratana, L., Bonotto, M., Bozza, C., Ongaro, E., Fanotto, V., Pelizzari, G., & Puglisi, F. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1282944 · Cited by 33
Lynce, F. C., Williams, J. T., Regan, M. M., Bunnell, C. A., Freedman, R. A., Tolaney, S. M., Chen, W. Y., Mayer, E. L., Partridge, A. H., Winer, E. P., et al. (2021) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-021-04245-x · Cited by 32
Type I interferons in pancreatic cancer and development of new therapeutic approaches
Blaauboer, A., Sideras, K., van Eijck, C. H. J., & Hofland, L. J. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103204 · Cited by 31
Tjandra, S. S., Hsu, C., Goh, Y. I., Gurung, A., Poon, R. W. M., Nadesan, P., & Alman, B. A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0686 · Cited by 30
Jiang, W., Zhang, C., Tian, Z., & Zhang, J. (2013) · Gene Therapy · doi:10.1038/gt.2013.31 · Cited by 30
Zhang, J., Asselin‐Paturel, C., Bex, F., Bernard, J., Chehimi, J., Willems, F., Caignard, A., Berglund, P., Liljeström, P., Burny, A., et al. (1997) · Gene Therapy · doi:10.1038/sj.gt.3300409 · Cited by 30
The role of the common gamma-chain family cytokines in γδ T cell-based anti-cancer immunotherapy
Acker, H. H. V., Campillo-Davó, D., Roex, G., Versteven, M., Smits, E., & Tendeloo, V. F. V. (2018) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2018.05.002 · Cited by 29
Immunity against breast cancer by TERT DNA vaccine primed with chemokine CCL21
Yamano, T., Kaneda, Y., Hiramatsu, S. H., Huang, S., Tran, A. N., Giuliano, A. E., & Hoon, D. S. �. (2007) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7701035 · Cited by 28
Fearon, D. T., & Janowitz, T. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01315-y · Cited by 28
A bacteria-based system expressing anti-TNF-α nanobody for enhanced cancer immunotherapy
Liu, L., Liu, X., Xin, W., Zhou, L., Huang, B., Han, C., Cao, Z., & Hua, Z. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01364-0 · Cited by 28
Deng, X., Shen, Y., Yi, M., Zhang, C. H., Zhao, B., Zhong, G., WeiyangLou, Xue, D., Leng, Q., Ding, J., et al. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28768 · Cited by 28
Self-citation
Cited by
The Role of Inflammation in Cancer: Mechanisms of Tumor Initiation, Progression, and Metastasis
Nishida, A., & Andoh, A. (2025) · Cells · doi:10.3390/cells14070488 · Cited by 270
Metadata
- Authors
- Yi, M., Li, T., Niu, M., Zhang, H., Wu, Y., Wu, K., & Dai, Z.
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2024-07-22
- Volume
- 9
- Issue
- 1
- Pages
- 176-176
- ISSN
- 2059-3635 (ISSN-L)
- OpenAlex
- W4400867712
- Cited by
- 455
- References
- 628
- FWCI
- 69.83
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.